Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Conditions:   Invasive Lobular Breast Carcinoma;   ER+ Breast Cancer;   HER2-negative Breast Cancer Interventions:   Drug: Entrectinib;   Drug: Letrozole;   Drug: Goserelin Sponsors:   Jules Bordet Institute;   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials